40
Participants
Start Date
June 1, 2024
Primary Completion Date
June 1, 2026
Study Completion Date
June 1, 2027
surufatinib combined with gemcitabine plus nab-paclitaxel
"Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\'s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery."
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER